## **Core Concept**
Multibacillary leprosy, also known as multibacillary (MB) leprosy, is a more severe form of leprosy characterized by a higher bacterial load. It includes lepromatous, borderline lepromatous, and borderline leprosy. The follow-up and monitoring of patients with multibacillary leprosy are crucial for assessing treatment response and detecting any potential complications or relapses early.

## **Why the Correct Answer is Right**
The correct answer, , indicates that follow-up for multibacillary leprosy is recommended for 5 years after completion of treatment. This prolonged follow-up period is necessary because multibacillary leprosy has a higher risk of relapse compared to paucibacillary leprosy. Monitoring for 5 years allows for the early detection of any signs of relapse, which can include new skin lesions, nerve involvement, or other symptoms.

## **Why Each Wrong Option is Incorrect**
- **Option A:** . This option suggests a follow-up period of 1 year, which is generally recommended for paucibacillary leprosy, not multibacillary leprosy.
- **Option B:** . A 2-year follow-up might seem reasonable but is not the recommended duration for multibacillary leprosy.
- **Option D:** . While a 10-year follow-up might provide additional safety, it is not the standard recommendation for multibacillary leprosy.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the World Health Organization (WHO) recommends a multidrug therapy (MDT) regimen for 12 months for multibacillary leprosy, followed by a 5-year surveillance period for relapse. Early detection of relapse is critical for preventing long-term disability.

## **Correct Answer:** . 5 years